Repros Shares Rally On Testicle-stimulation Drug Application

Repros Therapeutics Inc. shares rallied in the extended session Wednesday after the drug developer said the Food and Drug Administration will review its drug to treat overweight men with low testosterone. Repros shares jumped 19% to $10.08 on moderate volume. The company said the FDA will review its marketing application for enclomiphene citrate "to treat the underlying mechanism, insufficient stimulation of the testes by the pituitary, which causes secondary hypogonadism." Formerly known as Androxal, enclomiphene citrate is the company's lead product candidate.